A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Enliven Therapeutics, Inc. ELVN
Promising (early) (graded 2026-09-05, not re-checked) broader-coverage candidate · Enliven Therapeutics, Inc.
On FrontierLab's discovery record since 2026-06-18 (15 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-05), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | 0 |
| Rule of 40 | — |
| Net margin | — |
| Cash runway (months) | 120 |
| PEG | — |
| Price / sales | — |
Quality checklist
- ✓ Capital efficiency
- ✓ Share dilution — 27%
Fundamentals — snapshot as of 2026-09-05
| Stage | Early |
|---|---|
| Share issuance (YoY) | 27% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-1.64 |
| Burn multiple | — |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.98 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-05 |
Momentum context — a snapshot from 2026-09-05, not current
| Price at surface | $59.32 (as of 2026-09-05) |
|---|---|
| 52-week range | $14.785 – $62.32 |
| % off 52-wk high | -4.8% |
| RSI (14) | 56 |
| Relative volume | 1.4× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-05 (end-of-day). How grades are computed →